How can we realize the promise of personalized antidepressant medicines?

Cited by (178)

Items 101–178 of 178

1. Differential effects of healthcare worker burnout on psychotropic medication use and misuse by occupational level
   Rachel A. Hoopsick, Sylvia Las, Rachel C. F. Sun · 2023 · Social Psychiatry and Psychiatric Epidemiology
2. Genotype variant associated with add-on memantine in bipolar II disorder
   Sheng-Yu Lee, Shiou‐Lan Chen, Yun-Hsuan Chang, Shih‐Heng Chen, Chun-Hsieh Chu, San‐Yuan Huang, Nian‐Sheng Tzeng, Chen‐Lin Wang, Liang‐Jen Wang, I Hui Lee et al. · 2013 · The International Journal of Neuropsychopharmacology
3. Looking to the future of research in pediatric anxiety disorders
   John S. March · 2010 · Depression and Anxiety
4. Using Cognitive Neuroscience to Improve Mental Health Treatment: A Comprehensive Review
   Jessica A. Wojtalik, Shaun M. Eack, Matthew J. Smith, Matcheri S. Keshavan · 2018 · Journal of the Society for Social Work and Research
5. An endocrine perspective on the role of steroid hormones in the antidepressant treatment efficacy of transcranial magnetic stimulation
   Dennis J.L.G. Schutter, Jack van Honk · 2009 · Psychoneuroendocrinology
6. Imaging genetics: implications for research on variable antidepressant drug response
   Ulrich Rabl, Christian Scharinger, Markus Müller, Lukas Pezawas · 2010 · Expert Review of Clinical Pharmacology
7. The current and potential impact of genetics and genomics on neuropsychopharmacology
   Paul J. Harrison · 2013 · European Neuropsychopharmacology
8. Role of proteomics in biomarker discovery and psychiatric disorders: current status, potentials, limitations and future challenges
   Suman Patel · 2012 · Expert Review of Proteomics
9. Venlafaxine and sertraline does not affect the expression of genes regulating stress response in female MDD patients
   Ewa Banach, Aleksandra Szczepankiewicz, Anna Leszczyńska-Rodziewicz, Joanna Pawlak, Monika Dmitrzak‐Węglarz, Dorota Zaremba, Joanna Hauser · 2017 · Psychiatria Polska
10. The impact of policy on the growth of precision medicine
    Hyunjoon Kwon, Euy-Young Jung · 2018 · Health Policy and Technology
11. Biomarker Development for Brain-Based Disorders: Recent Progress in Psychiatry.
    James O Ebot Enaw, Alicia K. Smith · 2013 · Journal of Neurology and Psychology
12. “Now Is a Time for Optimism”: The Politics of Personalized Medicine in Mental Health Research
    Rüppel, Jonas · 2019 · Science, Technology, & Human Values
13. A Bayesian approach to joint modeling of matrix‐valued imaging data and treatment outcome with applications to depression studies
    Bei Jiang, Eva Petkova, Thaddeus Tarpey, Robert Todd Ogden · 2019 · Biometrics
14. Psychopharmacology: A house divided
    Charles E. Dean · 2010 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
15. Current pharmacological treatments for neurodegenerative diseases
    Anand Kumar Shukla, Prakashini Saroj Nilgirwar, Sindhu D. Bali · 2024 · Elsevier eBooks
16. ABCB1 variants and sex affect serotonin transporter occupancy in the brain
    L. Silberbauer, Lucas Rischka, Chrysoula Vraka, Annette M. Hartmann, Godber Mathis Godbersen, Cécile Philippe, Daniel Pacher, Lukas Nics, Manfred Klöbl, Jakob Unterholzner et al. · 2022 · Molecular Psychiatry
17. Die Zukunft der Depressionsforschung
    F. Holsboer · 2010 · Der Nervenarzt
18. Alterations in Systemic and Cognitive Glucocorticoid Sensitivity in Depression
    Allison E. Gaffey, Erin C. Walsh, Charlotte O. Ladd, Roxanne M. Hoks, Heather C. Abercrombie · 2018 · Biological Psychiatry Cognitive Neuroscience and Neuroimaging
19. Is evidence sufficient for evidence-based medicine?
    Hans‐Jürgen Möller · 2009 · European Archives of Psychiatry and Clinical Neuroscience
20. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan
    Sheng-Yu Lee, Shiou‐Lan Chen, Yun-Hsuan Chang, Po See Chen, San‐Yuan Huang, Nian‐Sheng Tzeng, Liang‐Jen Wang, I‐Hui Lee, Tzu‐Yun Wang, Kao‐Chin Chen et al. · 2015 · Journal of Psychiatric Research
21. Using Gene–Environment Interactions to Target Personalized Treatment in Mood Disorder
    Torsten Klengel, Elisabeth B. Binder · 2010 · Personalized Medicine
22. Improved Classification Accuracy of MCI Patients After Acupuncture Treatment: An fNIRS Study
    Usman Ghafoor, M. Atif Yaqub, M. N. Afzal Khan, Keum‐Shik Hong · 2019 · International Conference on Robotics and Automation in Industry (ICRAI)
23. Proteomic Studies on the Development of the Central Nervous System and Beyond
    Chenggang Zhang · 2010 · Neurochemical Research
24. Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive–compulsive disorder
    Amanda J. Lisoway, Gwyneth C. Zai, Arun Kumar Tiwari, Clement C.H. Zai, Karen G. Wigg, Vanessa Faria Gonçalves, Danning Zhang, Natalie Freeman, Daniel J. Müller, James L. Kennedy et al. · 2018 · Human Psychopharmacology Clinical and Experimental
25. Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point
    Florian Holsboer, Marcus Ising · 2024 · Pharmacopsychiatry
26. The COMT Val158Met Polymorphism Is Associated With Response to Add-on Dextromethorphan Treatment in Bipolar Disorder
    Sheng-Yu Lee, Shiou-Lan Chen, Tzu-Yun Wang, Yun-Hsuan Chang, Po Chen, San-Yuan Huang, Nian-Sheng Tzeng, Liang-Jen Wang, Hui I. Lee, K. Chen et al. · 2017 · Journal of Clinical Psychopharmacology
27. Serotonin transporter gene polymorphisms: Relation with platelet serotonin level in patients with primary Sjogren's syndrome
    Jasenka Markeljević, Helena Šarac, Nada Božina, Neven Henigsberg, M. Simic, L. Cicin Sain · 2015 · Journal of Neuroimmunology
28. Mécanismes des effets comportementaux de type anxiolytique/ antidépresseur de la fluoxétine (Prozac®)
    Quentin Rainer, Alain Michel Gardier, René Hen, Denis Joseph Paul David · 2009 · médecine/sciences
29. Dissecting the Pathophysiology of Depression with a Swiss Army Knife
    Pierre‐Marie Lledo · 2009 · Neuron
30. Neurogenic hypothesis and psychiatric disorders
    B. Lau, J. Lee, K. So · 2013 · Chinese Science Bulletin
31. Chronische Depression
    Thorsten Mikoteit, Martin Hatzinger · 2009 · Zeitschrift für Psychiatrie Psychologie und Psychotherapie
32. In search of the biological basis of mood disorders: Exploring out of the mainstream
    Igor Branchi, Mathias V. Schmidt · 2011 · Psychoneuroendocrinology
33. Changer d’antidépresseur : quand, comment, pourquoi ?
    David Gourion, André Galinowski, Laurent Baraille, Hernàn Picard · 2011 · L Encéphale
34. Biomarkers for the Development of Antidepressant and Anxiolytic Drugs
    Marcus Ising, Florian Holsboer · 2008 · Springer eBooks
35. Latent class modeling using matrix covariates with application to identifying early placebo responders based on EEG signals
    Bei Jiang, Eva Petkova, Thaddeus Tarpey, Robert Todd Ogden · 2017 · The Annals of Applied Statistics
36. Qualitative treatment-subgroup interactions in the antidepressant treatment of major depression: Application of QUINT to individual participant data from seven placebo-controlled randomized controlled trials
    Kazushi Maruo, Toshi A. Furukawa, Hisashi Noma, Hissei Imai, Kazutaka Ikeda, Shigeto Yamawaki · 2020 · Personalized Medicine in Psychiatry
37. Influence of the Serotonergic System Polymorphism on the Expression of Dental Anxiety
    Tanja Franćeski · 2018 · Acta Clinica Croatica
38. Redesigning antidepressant drug discovery
    Florian Holsboer · 2014 · Dialogues in Clinical Neuroscience
39. [Pharmacogenetics of depression in elderly patients].
    Julie Monnin, Émmanuel Haffen, D. Sechter, Pierre Vandel · 2009 · PubMed
40. Antidepressiva
    Edith Holsboer‐Trachsler, Florian Holsboer · 2011 · Springer eBooks
41. A Study of Candidate Genes in Depression and Disturbed Sleep
    Siddheshwar Utge · 2012 · Työväentutkimus Vuosikirja
42. Finding the pathology of major depression through effects on gene interaction networks
    Chris Gaiteri · 2011 · D-Scholarship@Pitt (University of Pittsburgh)
43. Genetic Markers for PTSD Risk and Resilience Among Survivors of the World Trade Center Attacks
    Rachel Yehuda · 2012 · PsycEXTRA Dataset
44. Individual response to antidepressants for depression in adults – a meta-analysis and simulation study
    Klaus Munkholm, Stephanie Homan, Philipp Homan · 2019
45. Targeted Development of an Optimised Formulation for 3D-Printing of a Sertraline Hydrochloride-Containing Drug Delivery System with Immediate-Release Characteristics Utilising a Mixture Design
    Mirco Bienhaus, Leif Neumann, Charlotte Müller, Frank Runkel · 2025 · Pharmaceutics
46. P01-82 - Heterogeneity of DSM-IV Major Depressive Disorder as a Consequence of Subthreshold Bipolarity
    Petra Zimmermann, T. Brueckl, Agnes Nocon, Hildegard Pfister, Roselind Lieb, Hans‐Ulrich Wïttchen, F. Holsboer, Jules Angst · 2010 · European Psychiatry
47. Depressive Störungen
    Gerd Laux · 2017 · Springer eBooks
48. Urinary Neurotransmitter Analysis as a Biomarker for Psychiatric Disorders
    Amnon Kahane · 2009
49. Clinical Impact of Pharmacogenetic Testing on Antidepressant Therapy
    F F Holsboer · 2017 · Annals of Depression and Anxiety
50. Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder
    Dean Frederick MacKinnon · 2015 · Wiley eBooks
51. Molecular mechanisms of D-cycloserine in a fear extinction posttraumatic stress disorder (PTSD) animal model
    Stefanie Malan‐Müller · 2014 · SUNScholar (Stellenbosch University)
52. Personalized Management of Neurological Disorders
    Kewal K. Jain · 2009 · Springer eBooks
53. Treating Bipolar Disorder and Schizophrenia with Biomedical Protocol
    Samantha M. Cardenas · 2014
54. Personalized Management of Neurological Disorders
    Kewal K. Jain · 2015 · Springer eBooks
55. Sleep Disorders: Psychiatric Aspects
    Jürgen Beck, Erich Seifritz, Edith Holsboer‐Trachsler · 2015 · Elsevier eBooks
56. Specific Actions, Patient Subgroups and Stages of Illness
    Siegfried F. Kasper · 2009
57. Stellenwert der Bioinformatik für die personalisierte Medizin
    Thomas Lengauer · 2013 · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
58. Psychobiological Investigation on Sociosexual Behavior in Male: Preclinical and Clinical Studies
    Harold Dadomo · 2009 · DSpaceUnipr (University of Parma)
59. Modelling Stress‐Related Mood Disorders in Animals
    Mathias V. Schmidt, Klaus V. Wagner, Xiao‐Dong Wang, Georgia Balsevich · 2015 · Wiley eBooks
60. Gene Regulation by Drugs Used to Treat Mood Disorders
    Xiaoyan Deng · 2011 · Otago University Research Archive (University of Otago)
61. Article Open Access
    Holly Lawford‐Smith · 2015
62. Personalized Management of Psychiatric Disorders
    Kewal K. Jain · 2015 · Springer eBooks
63. Performance evaluation of temporal features for detection of mild cognitive impairment: An fNIRS study
    Usman Ghafoor, M. Atif Yaqub, Keum‐Shik Hong · 2019 · International Automatic Control Conference
64. Seroto-nergic and noradrenergic modulation of emotion process-ing by sing dose antidepressants
    Annette Beatrix Brühl, Tina Kaffenberger, Uwe Herwig · 2010 · Medical Entomology and Zoology
65. Music Therapy and Biomarkers of Depression Treatment
    Jörg Christfried Fachner · 2016 · Annals of SBV
66. References
    2015 · Duke University Press eBooks
67. Depressive Störungen
    Gerd Laux · 2016 · Springer eBooks
68. Current awareness in human psychopharmacology
    2008 · Human Psychopharmacology Clinical and Experimental
69. Depressive Störungen
    Gerd Laux · 2011 · Springer eBooks
70. Personalized Neurology
    Kewal K. Jain · 2012 · Humana Press eBooks
71. Effects of the Aqueous Extract of Oxalis Barrelieri on Some Murine Models of Acute Depression
    2020 · ARC Journal of Neuroscience
72. Investigating the effect of acupuncture treatment on MCI patients using classification techniques
    M. N. Afzal Khan, Usman Ghafoor, Keum‐Shik Hong · 2022 · Asian Control Conference (ASCC)
73. Bibliography
    2022 · De Gruyter eBooks
74. IN VIVO ASSESSMENT OF SEROTONERGIC SIGNALING PATHWAYS UNDERLYING THE CORTICOLIMBIC RESPONSE TO THREAT IN HUMANS
    Patrick M. Fisher · 2010 · D-Scholarship@Pitt (University of Pittsburgh)
75. Effets comportementaux et neurogéniques des antidépresseurs dans un nouveau modèle d'anxiété/dépression chez la souris adulte
    Quentin Rainer · 2011
76. Potential muscular doping effects of anti-depressants
    Abdulkarim Tutakhail · 2019
77. Etude de la voie catabolique du tryptophane dans différentes conditions pathologiques : exemple de la phénylcétonurie et perspectives dans les maladies cardiovasculaires
    Lysiane Boulet · 2020 · theses.fr (ABES)
78. Comparative Analysis of Antidepressant Mechanisms and Side Effects: Network Pharmacology and Molecular Docking Study of Amitriptyline, Mirtazapine, and Escitalopram for Treating Major Depressive Disorder
    Chuanjun Zhuo, Qiuyu Zhang, Haitao Song, Jiatong Zou, Ranli Li, Xiaoyan Ma, Chen Xi-ming, Yachen Li, Lei Yang, Lina Wang et al. · 2026 · Depression and Anxiety